#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sarcoma Depression Hypersensitivity pneumonitis Extranodal marginal zone B-cell lymphoma (MALT type) Hypereosinophilic syndrome Breast angiosarcoma metastatic Systemic mastocytosis Alagille syndrome Nephrotic syndrome Systemic candida Optic glioma Chronic myelomonocytic leukaemia Vulval cancer Li-Fraumeni syndrome Retinal dystrophy More trials…

    Learn about Rare Diseases

    Haemophilia A with anti factor VIII – Basic Information Metachromatic leukodystrophy – Diagnostics Mantle cell lymphoma stage II – Life with Disease Lennox-Gastaut syndrome – Basic Information Malignant fibrous histiocytoma – Diagnostics Leukoencephalopathy – Diagnostics Hairy cell leukaemia – Basic Information Medulloblastoma recurrent – Trials in Disease Glycogen storage disease type V – Trials in Disease Sarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pentixafor Gallium Ga-68 Ethambutol Anthoxanthum Odoratum HUMAN FIBROBLASTS Gen3017 Ds-2325A Ginisortamab ALN-4324 Doxazosin Pegaspargase Odm-208 Prasterone Fampridine Ipatasertib Asciminib Jab-21822 Doxylamine Hydrogen Succinate Dimethyl Fumarate Opelconazole Sodium Acetate Trihydrate More therapies…

    Learn about Your Condition

    Neoplasm Stress Herpes simplex meningitis Post cardiac arrest syndrome Pancreatic carcinoma recurrent Neuroblastoma Pertussis Still's disease Fibromyalgia Elderly Thromboembolectomy Candida infection Extra-osseous Ewing's sarcoma Strongyloidiasis Mesothelioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metabolic dysfunction-associated steatohepatitis

  • Study on Liver Fibrosis Assessment Using 68Ga-FAPI-46 Imaging in Patients with Suspected or Confirmed Nonalcoholic Steatohepatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

    Recruiting

    3 1
    Investigated Diseases:
    • Hepatic fibrosis
    Investigated Drugs:
    • Efruxifermin
    France Germany Italy Poland Spain

  • Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Drugs:
    • Efruxifermin
    Belgium Denmark France Germany Greece Italy +2

  • Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

    Recruiting

    2 1
    Investigated Drugs:
    • Namodenoson
    Bulgaria Poland Romania

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!